# mulTi-Arm Therapeutic Study in Pre-ICu Patients Admitted With Covid-19 - Repurposed Drugs (TACTIC-R)

> **NCT04390464** · PHASE4 · UNKNOWN · sponsor: **Cambridge University Hospitals NHS Foundation Trust** · enrollment: 1167 (estimated)

## Conditions studied

- COVID19

## Interventions

- **DRUG:** Ravulizumab
- **DRUG:** Baricitinib
- **OTHER:** Standard of care

## Key facts

- **NCT ID:** NCT04390464
- **Lead sponsor:** Cambridge University Hospitals NHS Foundation Trust
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-05-08
- **Primary completion:** 2021-05-07
- **Final completion:** 2022-05-01
- **Target enrollment:** 1167 (ESTIMATED)
- **Last updated:** 2020-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04390464

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04390464, "mulTi-Arm Therapeutic Study in Pre-ICu Patients Admitted With Covid-19 - Repurposed Drugs (TACTIC-R)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04390464. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*